ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
124.305,57
-0,34%
S&P 500
5.304,72
0,70%
US Dollar vs BRL
5,13862
-0,55%
Bitcoin
69.250,00
1,05%
Brent Oil
81,965
0,00%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. Canadá
  5. TSX
  6. ProMIS Neurosciences Inc (PMN)

  7. ProMIS Neurosciences Inc (PMN) Notícias

PMN

ProMIS Neurosciences (PMN)

ProMIS Neurosciences Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:TSX:PMN
DataHoraFonteTítuloCódigoCompanhia
18/04/202210:05PR Newswire (US)Argus Research Initiates Equity Report Coverage on ProMIS Neurosciences, Inc. (TSX:PMN & OTCQB: ARFXF)TSX:PMNProMIS Neurosciences Inc
18/08/202109:15PR Newswire (Canada)L'OCRCVM permet la reprise de la négociation - PMNTSX:PMNProMIS Neurosciences Inc
18/08/202109:13PR Newswire (Canada)IIROC Trade Resumption - PMNTSX:PMNProMIS Neurosciences Inc
17/08/202117:53PR Newswire (Canada)Suspension de la négociation par l'OCRCVM - PMNTSX:PMNProMIS Neurosciences Inc
17/08/202117:50PR Newswire (Canada)IIROC Trading Halt - PMNTSX:PMNProMIS Neurosciences Inc
18/11/201909:30PR Newswire (Canada)ProMIS Neurosciences Completes First Closing of Private PlacementTSX:PMNProMIS Neurosciences Inc
14/11/201909:30PR Newswire (Canada)ProMIS Neurosciences Announces Third Quarter 2019 ResultsTSX:PMNProMIS Neurosciences Inc
13/11/201909:30PR Newswire (Canada)ProMIS Neurosciences Undertaking $6.5M Private PlacementTSX:PMNProMIS Neurosciences Inc
07/11/201909:30PR Newswire (US)ProMIS Neurosciences outlines best-in-class approach to amyloid-beta-targeting drug candidates for Alzheimer's diseaseTSX:PMNProMIS Neurosciences Inc
24/10/201904:00PR Newswire (US)ProMIS Neurosciences issues Chairman's update memorandum and white paper on Alzheimer's diseaseTSX:PMNProMIS Neurosciences Inc
23/10/201910:49PR Newswire (US)ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43TSX:PMNProMIS Neurosciences Inc
17/10/201908:30PR Newswire (US)ProMIS Neurosciences advances Alzheimer's disease program targeting neurotoxic forms of tauTSX:PMNProMIS Neurosciences Inc
08/10/201908:30PR Newswire (US)ProMIS Neurosciences Identifies Novel Antibody Candidates for Multiple System AtrophyTSX:PMNProMIS Neurosciences Inc
03/09/201908:30PR Newswire (US)ProMIS Neurosciences to Present at HC Wainwright Investment ConferenceTSX:PMNProMIS Neurosciences Inc
27/08/201908:30PR Newswire (Canada)ProMIS Neurosciences Appoints Internationally Recognized Researcher in Alzheimer's Disease in Down Syndrome Dr. Andre Strydom...TSX:PMNProMIS Neurosciences Inc
13/08/201908:30PR Newswire (Canada)ProMIS Neurosciences Announces Second Quarter 2019 ResultsTSX:PMNProMIS Neurosciences Inc
24/07/201908:30PR Newswire (Canada)ProMIS Neurosciences Announces Results of Annual Meeting of ShareholdersTSX:PMNProMIS Neurosciences Inc
18/07/201916:00PR Newswire (US)ProMIS Neurosciences Highlights Data for PMN310 at AAIC 2019TSX:PMNProMIS Neurosciences Inc
10/07/201908:30PR Newswire (Canada)ProMIS Neurosciences to Present Data at 2019 Alzheimer's Association International ConferenceTSX:PMNProMIS Neurosciences Inc
09/07/201908:30PR Newswire (US)ProMIS Neurosciences' Data for Alzheimer's Disease Clinical Candidate PMN310 Published in Scientific ReportsTSX:PMNProMIS Neurosciences Inc
27/06/201908:30PR Newswire (Canada)ProMIS Neurosciences' PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed AntibodiesTSX:PMNProMIS Neurosciences Inc
26/06/201908:30PR Newswire (Canada)ProMIS Neurosciences Closing Private PlacementTSX:PMNProMIS Neurosciences Inc
19/06/201908:30PR Newswire (US)ProMIS Neurosciences Appoints Renowned Parkinson's Disease Expert Dr. C. Warren Olanow to Scientific Advisory BoardTSX:PMNProMIS Neurosciences Inc
05/06/201908:30PR Newswire (US)ProMIS Neurosciences Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific ConferenceTSX:PMNProMIS Neurosciences Inc
29/05/201908:30PR Newswire (US)ProMIS Neurosciences' Eugene Williams to Present at JLABS' Conference on Innovations in Neurodegenerative DiseasesTSX:PMNProMIS Neurosciences Inc
28/05/201908:30PR Newswire (US)ProMIS Neurosciences Identifies Novel Antibodies for Alzheimer's Disease with Selectivity for the Neurotoxic Form of TauTSX:PMNProMIS Neurosciences Inc
14/05/201908:30PR Newswire (US)ProMIS Neurosciences Announces First Quarter 2019 ResultsTSX:PMNProMIS Neurosciences Inc
23/04/201908:30PR Newswire (US)ProMIS Neurosciences to Participate in the Think Equity Investor ConferenceTSX:PMNProMIS Neurosciences Inc
26/03/201908:30PR Newswire (US)ProMIS Neurosciences to Participate in Microcap Spring Investor Summit 2019TSX:PMNProMIS Neurosciences Inc
21/03/201915:47PR Newswire (US)Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer's DiseaseTSX:PMNProMIS Neurosciences Inc
 Apresentando as notícias mais relevantes sobre:TSX:PMN

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
PSVM11
PORTO SUDESTE
BOV
HOOT4
HOTEIS OTHON PN
BOV
GOLL4
GOL PN
BOV
PETZ3
Pet Center Comercio E Pa... ON
BOV
AMER3
Americanas ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados